HANDA ONCOL announced Wednesday that the FDA approved its investigational therapy for the selected indication on September 3, 2026, which is anticipated to intensify competitive pressure on existing market participants and potentially disrupt the revenue forecasts of key players in the specialized therapeutic space. Following this regulatory clearance, the company is poised to leverage its strong manufacturing capabilities to rapidly scale commercial distribution and secure a dominant market share.